


2<sup>nd</sup> February, 2022

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

THS ENDED 31ST DECEMBER, 2021				Rs. in Lakhs	
NINE MONTHS ENDED				Year Ended	
	31.12.2021	31.12.2020	31.03.2021		
020	Un-Audited	Un - Audited	Audited		
46	3,608.56	3,569.39	5177.52		
00	24.47	0.00	7.87		
46	3,633.03	3,569.39	5,185.38		
32	3.44	72.61	(269.86)		
	-	-	-		
56	498.00	479.75	990.56		
6	661.94	590.23	856.99		
9	523.59	383.81	559.14		
0	312.72	227.63	352.99		
8	1,024.21	1,060.97	1833.38		
1	3023.90	2815.00	4323.20		
6	609.12	754.39	862.18		
0	0.00	0.00	0.00		
5	609.12	754.39	862.18		
9	124.63	196.14	135.76		
2)	196.25	19.75	157.97		
7	320.88	215.89	293.74		
0	288.24	538.50	568.44		
	0.00	0.00	0.00		
	288.24	538.50	568.44		
	1420.45	1288.75	1341.95		
	2.03	4.18	4.24		
	1.95	4.12	4.20		
For Vivo Bio Tech Ltd					
					
M. Kalyan Ram Whole Time Director DIN:02012580					

# Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Gajwel - 502311

o.com, CIN: L65993TG1987PLC007163

FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021										Rs. in Lacs	
	QUARTER ENDED				NINE MONTHS ENDED				Year Ended		
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2021	31.12.2020	31.12.2020	31.03.2021	31.03.2021		
	Un-Audited	Un-Audited	Un - Audited	Un - Audited	Un - Audited	Un - Audited	Un - Audited	Audited	Audited		
	1292.02	1016.83	1187.46	1187.46	3608.56	3569.39	5177.52				
	0.00	3.01	0.00	0.00	25.09	0.00	7.87				
	1292.02	1019.84	1187.46	1187.46	3633.65	3569.39	5185.38				
WIP	(12.27)	(115.67)	83.32	83.32	3.44	72.61	(269.86)				
	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	132.65	163.63	158.56	158.56	498.00	479.75	990.56				
	239.36	203.44	174.96	174.96	661.94	590.23	856.99				
	171.03	173.86	134.02	134.02	523.59	391.36	559.14				
	120.37	106.38	54.30	54.30	312.72	227.63	353.00				
	356.80	381.61	292.18	292.18	1024.21	1060.97	1833.59				
	1007.94	913.24	897.33	897.33	3023.90	2815.00	4323.41				
	284.08	106.60	290.13	290.13	609.74	754.39	861.97				
	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	284.08	106.60	290.13	290.13	609.74	754.39	861.97				
loss (Net of Tax) II+IX ) (In lakh Units)	43.76	30.30	103.79	103.79	124.63	196.14	135.76				
	103.11	48.59	(36.42)	(36.42)	196.25	19.75	157.97				
	146.87	78.89	67.37	67.37	320.88	215.89	293.74				
	137.21	27.71	222.76	222.76	288.86	538.50	568.23				
	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	137.21	27.71	222.76	222.76	288.86	538.50	568.23				
	1420.45	1420.45	1288.75	1288.75	1420.45	1288.75	1341.95				
	0.97	0.20	1.73	1.70	2.03	4.18	4.23				
	0.93	0.19	1.70	1.70	1.95	4.12	4.19				

For Vivo Bio Tech Ltd



M. Kalyan Ram  
Whole Time Director  
DIN:02012580

**Notes:**

1. The above Un-Audited Financial Results for the Quarter and Nine Months ended 31<sup>st</sup>,

December 2021 have been reviewed



**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS

Tel. : (91-40) 2311 9499  
E-mail : [pcnassociates@yahoo.com](mailto:pcnassociates@yahoo.com)

WILLIAMS & ASSOCIATES

San Diego, California

Phone: (619) 591-1234

William's Registration No. 0160160



**P C N & ASSOCIATES**

Tel. : (91-40) 2311 9499



**P C N & ASSOCIATES**

**CHARTERED ACCOUNTANTS**

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

"The Statement" includes the Ind AS financial results of the following entities:

- I. Vivo Bio Labs Private Limited
- II. Vivo Bio Discovery Services Private Limited
- III. Surlogic Life Consultancy Private Limited
- IV. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above and based on the considerations of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We didn't review the interim financial results and other unaudited financial information